


MAGE3 Antibody / Melanoma-associated antigen 3 (F55111)


Catalog No.	Formulation	Size
F55111-0.4ML	In 1X PBS, pH 7.4, with 0.09% sodium azide	0.4 ml
F55111-0.08ML	In 1X PBS, pH 7.4, with 0.09% sodium azide	0.08 ml

Bulk quote request


Availability	1-2 business days
Species Reactivity	Human
Format	Purified
Clonality	Polyclonal (rabbit origin)
Isotype	Rabbit Ig
UniProt	P43357
Applications	Western Blot : 1:500-1:1000 Immunohistochemistry (FFPE) : 1:10-1:50 Flow Cytometry : 1:10-1:50 per million cells in 0.1ml
Limitations	This MAGE3 antibody is available for research use only.



IHC staining of FFPE human breast cancer tissue with MAGE3 antibody. HIER: steam section in pH6 citrate buffer for 20 min and allow to cool prior to staining.



Western blot testing of human Jurkat cell lysate with MAGE3 antibody. Predicted molecular weight ~35 kDa.



Flow cytometry testing of human Jurkat cells with MAGE3 antibody; Blue=isotype control, Green= MAGE3 antibody.

Description

MAGE3, also known as Melanoma-associated antigen 3, is a protein that is commonly expressed in melanoma cells. It plays a crucial role in tumor growth and progression, making it an attractive target for cancer therapy. Research has shown that targeting MAGE3 can effectively inhibit the growth of melanoma cells, leading to the potential development of new treatments for this aggressive form of cancer. One of the most exciting aspects of MAGE3 is its ability to stimulate the immune system to recognize and attack cancer cells. This makes it a promising candidate for immunotherapy, a cutting-edge treatment that harnesses the power of the body's own immune system to fight cancer. By targeting MAGE3, researchers hope to develop more effective and targeted therapies for melanoma patients. Recent studies have highlighted the potential of MAGE3 as a biomarker for predicting the prognosis of melanoma patients. By measuring the levels of MAGE3 in tumor samples, doctors can better tailor treatment plans and improve patient outcomes.

Application Notes

The stated application concentrations are suggested starting points. Titration of the MAGE3 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Immunogen

A portion of amino acids 283-314 from the human protein was used as the immunogen for the MAGE3 antibody.

Storage

Aliquot the MAGE3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.